In March 2020, several weeks after the initial global spread of SARS-CoV-2, WHO
By the time the study is completed at the end of 2020year, it covered 405 hospitals in 30 countries and recruited more than 11,000 participants. The scientists found that all four antiviral drugs tested had little effect on overall mortality or length of hospital stay.
WHO has now begun the second phase of its globala research program called Solidarity Plus. As part of this project, experts will study three pre-existing drugs - artesunate, imatinib and infliximab.
All three investigational drugs have anti-inflammatory properties, but work in different ways.
Artesunate is a drug used to treat malaria. Listed on the WHO Model List of Essential Medicines, a list of essential medicines compiled by the World Health Organization.
Imatinib - antileukemic cytostatica drug, one of the representatives of a new class of targeted cytostatics, selectively affecting cells that have certain genetic defects characteristic of tumors.
Infliximab - specific immunosuppressivea drug that selectively suppresses autoimmune reactions due to specific binding to one of the immune cytokines - the so-called "tumor necrosis factor alpha".
The WHO noted that these drugs do not helppatients in the early stages of the disease. In fact, if immunosuppressants are given too early in the course of an illness, it can make the situation much worse.
Read more
See the fastest hypersonic aircraft
The slowing down of the Earth's rotation caused the release of oxygen on the planet
What Happens to Cryptocurrency: From Rise and Fall to State Recognition